Business Wire

LEAPMOTOR

28.6.2022 14:02:14 CEST | Business Wire | Press release

Share
Leapmotor's 100,000th Mass-Produced Vehicle Rolls off the Line

Today, Leapmotor's 100,000th mass-produced vehicle rolled off the line. On June 28, 2019, Leapmotor's first mass-produced vehicle, S01, rolled off the line. It took three years from S01 to C11 (the 100,000th mass-produced vehicle), realizing the leap from 0 to 100,000 in the field of intelligent EV. And it only took half a year to reach 100,000 vehicles from 50,000.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220628005686/en/

Zhu Jiangming, the Founder and Chairman of Leapmotor, said in a thank-you letter that seven years witnessed Leapmotor's winning the trust of 100,000 users. In addition to gratitude, Leapmotor will go forward with more friends by adhering "guard against arrogance, and consistency in original aspiration". We will continue to make breakthroughs and innovation in the core technology field, and focus on the user-centered concept to keep moving with our users, thus delivering the finest smart mobility experience to all consumers.

After seven years of independent full-suite of R&D, the Leapmotor has ushered in a phenomenal development in 2022:

In March, the monthly delivery volume of Leapmotor vehicles exceeded the threshold of 10,000 units for the first time;
In April, launched the first mass-produced model with CTC technology in China - Released the integrated technology of battery chassis of Leapmotor intelligent power CTC;
In May, Leapmotor C01, the electric vehicle equipped with CTC technology without battery pack, launched a pre-sale, and the current order has reached 60000 units; at the same time, the delivery volume reached a new high in May, achieving a year-on-year growth of more than 200% for 14 consecutive months;
In June, the 100,000th mass-produced vehicle was off the production line.

Leapmotor independently controls the core technology. Since 2015, Leapmotor has established a short-term difficult but long-term correct route of full-suite of R&D, striving to build the core competitiveness of technological innovation, which has greatly enhanced Leapmotor's ability to resist external risks under uncertain factors.

Moreover, in order to cope with the uncertainty of the supply chain, Leapmotor also made a layout in advance, built the mechanism of multi supply enterprises and multi-regional planning, and effectively improved the ability of the supply chain to resist risks.

With the further innovation and improvement of Leapmotor product matrix, Leapmotor will brave winds and waves and continue to deliver the finest smart mobility experience to all consumers.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ThetaRay Named World’s Best Software Provider for AML and Sanctions Screening in the 2026 Euromoney Transaction Banking Awards5.11.2026 19:30:00 CET | Press release

Recognition caps standout year alongside ThetaRay’s Top 10 (#8) ranking in the 2026 Chartis Financial Crime and Compliance50 (FCC50) and category win for Explainable AI. ThetaRay, a global leader in AI-native financial crime compliance infrastructure, has been named The World’s Best Software Provider for AML and Sanctions Screening at the 2026 Euromoney Transaction Banking Awards. Evaluated by Euromoney’s editorial and research team, ThetaRay was recognized for technology excellence, verifiable performance, and advancing the modern transaction banking value chain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261105714764/en/ The recognition reinforces ThetaRay’s standing as foundational compliance infrastructure for global institutions, closely following Chartis Research ranking ThetaRay #8 globally in the Financial Crime and Compliance50 (FCC50) 2026 report and naming the company a Category Winner for Explainable AI. “Our

Arthur D. Little: H1 2026 Private Capital Fundraising Strengthens While Market Sentiment Highlights Investor Shift to Europe over US and Asia5.11.2026 18:58:00 CET | Press release

H1 fundraising up 6% year-on-year as 43% of LPs see geopolitical volatility favouring European funds AI usage dominates industry attention, defence leads target investment themes Invest Europe, the association representing Europe’s private equity, venture capital and infrastructure sectors, as well as their investors, today released ‘Investing in Europe: Private Equity Activity H1 2026’ and ‘The Insight: State of the European Private Equity Industry 2026’, an annual market sentiment report published jointly with global management consultancy Arthur D. Little (ADL). Together, these show increased fundraising for European private equity and venture capital versus the same period last year, stronger investor allocation expectations for Europe, and declining appetite for the US and Asia. The sentiment report also demonstrates how AI is reshaping the industry and portfolio companies, while defence-related themes are topping GPs’ target investments. GPs (General Partners/fund managers of PE

Angelalign Appoints Marco Gadola as Senior Advisor5.11.2026 18:35:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel”) http://www.angelaligner.com, a global clear aligner leader, today announced that Marco Gadola has joined Angel as Senior Advisor. In this role, Marco will advise the Board and senior management on culture, strategy and governance. Marco, who has held many leadership positions, is well-known as a former CEO of Straumann Group, a leading global medical device company focused on dentistry. Marco said he is excited to join Angel. “I’ve followed Angel for 10 years and have seen how it has evolved,” he said, “It’s grown from a regional leader in innovative clinical solutions and high-quality products, to a worldwide organization trusted by orthodontic specialists, with an impressive innovation pipeline.” Fox Hu, CEO of Angel, said: “Angel has strong core capabilities, but we must continue to improve to serve orthodontists even better. We welcome Marco as an advocate for our customers and employees around the world and to help us build an outstan

Boomi Named a Visionary in the 2026 Gartner® Magic Quadrant™ for AI Agent Management Platforms5.11.2026 17:25:00 CET | Press release

Boomi governs agents, with flexibility across cloud, hybrid, and fully on-premises deployments behind the firewall. Boomi, the data activation company for AI, today announced it has been recognized as a Visionary in the 2026 Gartner® Magic Quadrant™ for AI Agent Management Platforms. Boomi delivers agent management capabilities through the Agent Control Plane. Boomi believes this placement reflects its approach to solving one of the biggest hurdles in turning AI into ROI, by providing critical AI infrastructure that connects, governs, and controls AI costs across agents and skills from native and third-party providers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261105515847/en/ Boomi Named a Visionary in the 2026 Gartner® Magic Quadrant™ for AI Agent Management Platforms Key Takeaways Boomi has been recognized as a Visionary in the 2026 Gartner® Magic Quadrant™ for AI Agent Management Platforms. A complimentary copy of t

Biocodex Invests €15 Million in a New Industrial Platform for Live Biotherapeutic Products5.11.2026 16:04:00 CET | Press release

Biocodex, an independent French pharmaceutical company, announces a €15 million investment to develop an industrial platform in Beauvais, France, dedicated to Live Biotherapeutic Products (LBPs) derived from the microbiome. Building on more than 70 years of expertise in living microorganisms, microbiota, fermentation and pharmaceutical manufacturing, Biocodex aims to support its partners and, ultimately, its own programs, from research through to clinical and commercial production. The project aims to strengthen healthcare and industrial sovereignty in the field of next-generation microbiome-based therapies. Scientific advances in microbiome science are opening up new therapeutic perspectives, notably in oncology, inflammatory bowel diseases, certain rare diseases and women’s health. Moving from research to pharmaceutical production requires facilities adapted to living microorganisms and pharmaceutical requirements. Open to biotechnology companies worldwide, it will support LBP progra

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye